Acute myeloid leukemia (AML) remains the most common form of acute leukemia in adults, with a 5-year survival rate of 30.5% among all patients diagnosed between 2012 and 2018 in the United States. 1 Due to a combination of advances in supportive
Search Results
Jan Philipp Bewersdorf, Scott F. Huntington, and Amer M. Zeidan
Peter L. Greenberg
undergo evolution to or toward acute myeloid leukemia (AML). Pathogenetic mechanisms contributing to clinical phenotypes relate to critical molecular and biologic features. This article focuses on recently reported advances that describe major components
Nathan J. Moore, Megan Othus, Anna B. Halpern, Nicholas P. Howard, Linyi Tang, Kyle E. Bastys, Mary-Elizabeth M. Percival, Paul C. Hendrie, Garrett A. Hartley, Verna L. Welch, Elihu H. Estey, and Roland B. Walter
Background Adults with acute myeloid leukemia (AML) or other high-grade myeloid neoplasms typically remain hospitalized during the several weeks of profound pancytopenia after intensive induction chemotherapy. However, the need for
Sandipkumar H. Patel, Sumithira Vasu, Ling Guo, Olivia Lemaster, John C. Byrd, and Alison Walker
intravenously on days 1–3) because of the presence of the IDH1 mutation, which is present in 7% to 14% of patients with acute myeloid leukemia (AML). 5 On day 8 of 7+3 treatment, she developed hemoptysis and blurry vision due to bilateral preretinal
Kamya Sankar and Brady L. Stein
transformation to myelofibrosis (MF) or acute myeloid leukemia (AML). In 2005, the discovery of molecular abnormalities associated with PV and ET were instrumental in understanding the pathophysiologic and clinical manifestations of these disorders. 1 JAK2
Chezi Ganzel, Dan Douer, and Martin S. Tallman
cells that may have remained after previous intensive consolidation. Currently, the prevailing consensus is that maintenance therapy is mandatory in patients with acute lymphoblastic leukemia (ALL), whereas those with acute myeloid leukemia (AML) are
Presented by: Mazyar Shadman and Deborah M. Stephens
and cons of chemoimmunotherapy versus ibrutinib,” he said. After FCR, the risk of treatment-related myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) is 5%. However, patients with mutated IGHV have durable long-term remissions from FCR
Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, James M. Foran, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Mark A. Schroeder, Paul J. Shami, Richard M. Stone, James E. Thompson, and Peter Westervelt
for MDS to evolve into acute myeloid leukemia (AML). In the general population, MDS occur in 5 per 100,000 people. However, among individuals older than 70 years, the incidence increases to between 22 and 45 per 100,000 and increases further with age
Akriti Jain and Kendra Sweet
have been recognized to be associated with various myeloid neoplasms, including chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML), and have also been hypothesized to be clonally related to BPDCN
Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Brandon McMahon, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolaos Papadantonakis, Philip Pancari, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Vishnu Reddy, Lindsay A.M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, and Hema Sundar
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.
